Pacific Biomarkers, Inc. Reports Second Quarter Operating Results

Pacific Biomarkers, Inc. (OTC.BB:PBMC), a leading provider of specialized biomarker and contract research services, today announced its operating results for the second quarter and first half of FY2011.

For the three months ended December 31, 2010 (the second quarter of FY2011), revenue increased 20% to $2,532,069, compared with $2,113,795 in the second quarter of FY2010. Operating loss was $202,728 in the second quarter of FY2011, versus an operating loss of $307,037 in the prior-year period. The Company reported net loss of $349,218, or $0.02 per share, for the three months ended December 31, 2010, compared with net loss of $457,629, or $0.03 per share, in the three months ended December 31, 2009.

Revenue for the six months ended December 31, 2010 increased 22% to $5,385,602, compared with $4,415,170 during the corresponding period of the previous fiscal year. Operating loss was $250,252 in the first half of FY2011, versus an operating loss of $520,745 in the same period last year. Net loss for the six months ended December 31, 2010 totaled $551,581, or $0.03 per share, compared with net income of $730,799, or $0.04 per share, for the comparable six-month period in FY2010.

"Our results for the three months ended December 31, 2010 are a reflection of the challenging drug development environment. While revenue increased from the prior year, gross profit was still short of plan. We remain confident that we are well positioned to execute our strategic plan for continued growth in the specialty laboratory and our biomarker services area," commented Ron Helm, Chief Executive Officer of Pacific Biomarkers. "We benefited from a large contract in the first two quarters, while other revenues reflected what we have seen in our clinical services market in line with what other Contract Research Organizations (CROs) have reported."

Mr. Helm continued, "The Company's result last year demonstrated that the drug development marketplace continues to challenge organizations supporting clinical trial work as well as biomarker development. We believe that our strategy of broadening our biomarker services offering continues to be a sound move even in view of somewhat mixed results so far for this fiscal year -- down 15% for the quarter, but up 4% for the six month period. The current market conditions may challenge us for a time and we have implemented measures to control costs including a reduction in force during the second quarter and other operating expense reductions. We believe we will be positioned appropriately as the market improves."

"We believe PBI's improved financial performance for the first half of Fiscal 2011 is encouraging. Nonetheless, we have made substantial adjustments to our current operating plan in view of soft margins and increased expense levels. We anticipate improvement in demand for our broad portfolio of specialty laboratory and biomarker services. We have identified the biomarker services area as the long-term growth driver in a market segment where demand is strong and there continue to be no dominant players in this area," concluded Helm.

For additional information, see Pacific Biomarkers' quarterly report filed with the SEC on Form 10-Q for the fiscal quarter ended December 31, 2010 and its annual report filed with the SEC on Form 10-K for the fiscal year ended June 30, 2010.

About Pacific Biomarkers, Inc.
Established in 1989, PBI provides biomarker laboratory services and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The Company provides expert services in the areas of cardiovascular and musculoskeletal diseases, diabetes, obesity, and nutrition. The PBI laboratory is accredited by the College of American Pathologists, New York State, and the Lipid Standardization Program. PBI's clients include many of the world's largest pharmaceutical, biotech, and diagnostic companies. PBI also provides clinical biomarker services focusing on the emerging field of biomarker assay development and testing. Services include validating and performing custom assays for novel clinical biomarkers, immunogenicity testing, mass spectrometry, and multiplex testing. PBI is headquartered in Seattle, Washington, and its common stock trades on the OTC Bulletin Board under the symbol "PBMC."

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release includes forward-looking statements including, but not limited to, the following: growth in revenues; results of business development activities; financial results; future growth; and growth and demand for our services, particularly our biomarker services. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ materially from those described in the forward-looking statements. These risks include, but are not limited to, the following: the Company's ability to enter into contracts for its laboratory testing or biomarker services; client changes or early terminations of studies; the success of marketing and business development efforts, and competitive factors; the Company's ability to manage growth; and other risks and uncertainties set forth in periodic filings with the U.S. Securities and Exchange Commission (including Form 10-K for the year ended June 30, 2010).

View Full Report

Source: Marketwire